REGENOSINE INC

Biotech · Private

Lipo-Ade, a liposomal adenosine therapeutic for intraarticular injection to regenerate cartilage in osteoarthritis patients

Grants
$1.7M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Treatment and prevention of osteoarthritis with an intra-articular disease-modifying regenerative therapy$860,384
Federal grantDepartment of Health and Human Services · Phase II · Treatment and prevention of osteoarthritis with an intra-articular disease-modifying regenerative therapy$811,405
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1133PROLACTA BIOSCIENCE INC—$65M
1134CalciMedica Subsidiary, Inc.—$67M
1135Vergent Bioscience, Inc.—$54M
1136REGENOSINE INC——
1137Synata Bio, Inc.—$52M
1138SYNSORYBIO, INC.——
1139ELEX BIOTECH, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 2
  • Liposomes Encapsulating Adenosineapplication
  • Liposomes Encapsulating Adenosineapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.